Fofana Bakary, Takala-Harrison Shannon, Ouattara Amed, Sagara Issaka, Togo Amadou H, Diakité Hamadoun, Keita Mohamed, Sanogo Kassim, Touré Sekou, Doumbo Ogobara K, Djimde Abdoulaye A
Malaria Research and training Center/Department of Epidemiology of Parasitic diseases/ Faculty of Pharmacy and Faculty of Medicine and Odontostomatology/University of Sciences, Techniques and Technologies of Bamako, Mali.
Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland.
Am J Trop Med Hyg. 2022 Feb 28;106(4):1209-1214. doi: 10.4269/ajtmh.21-0788. Print 2022 Apr 6.
Throughout a phase IIIb/IV efficacy study of repeated treatment with four artemisinin-based combination therapies, significant heterogeneity was found in the number of clinical episodes experienced by individuals during the 2-year follow-up. Several factors, including host, parasite, and environmental factors, may contribute to the differential malaria incidence. We aimed to identify risk factors of malaria incidence in the context of a longitudinal study of the efficacy of different artemisinin-based combination therapy regimens in Bougoula-Hameau, a high-transmission setting in Mali. Risk factors including age, residence, and treatment regimen were compared among individuals experiencing eight or more clinical episodes of malaria ("high-incidence group") and individuals experiencing up to three clinical episodes ("low-incidence group"). Consistent with the known association between age and malaria risk in high-transmission settings, individuals in the high incidence group were significantly younger than individuals in the low-risk group (mean age, 7.0 years versus 10.6 years, respectively; t-test, P < 0.0001). Compared with individuals receiving artemether-lumefantrine, those receiving artesunate-amodiaquine had greater odds of being in the high-incidence group (odds ratio [OR], 2.24; 95% CI, 1.03 - 4.83, P = 0.041), while individuals receiving dihydroartemisinin-piperaquine had a lower odds of being in high incidence group (OR: 0.30, 95% CI, 0.11-0.85; P = 0.024). Individuals residing in the forested areas of Sokourani and Karamogobougou had significantly greater odds of being in the high-incidence group compared with individuals residing in the semi-urban area of Bougoula-Hameau 1 (Karamogobougou: OR, 3.68; 95% CI, 1.46-9.31; P = 0.0059; Sokourani: OR, 11.46; 95% CI, 4.49-29.2; P < 0.0001). This study highlights the importance of fine-mapping malaria risks even at sub-district levels for targeted and customized interventions.
在一项关于四种青蒿素联合疗法重复治疗的IIIb/IV期疗效研究中,发现在2年随访期间个体经历的临床发作次数存在显著异质性。包括宿主、寄生虫和环境因素在内的几个因素可能导致疟疾发病率的差异。我们旨在通过对马里高传播地区布古拉 - 哈莫的不同青蒿素联合治疗方案疗效进行纵向研究,确定疟疾发病率的风险因素。在经历八次或更多次疟疾临床发作的个体(“高发病率组”)和经历至多三次临床发作的个体(“低发病率组”)之间,比较了年龄、居住地点和治疗方案等风险因素。与高传播地区年龄与疟疾风险之间已知的关联一致,高发病率组的个体明显比低风险组的个体年轻(平均年龄分别为7.0岁和10.6岁;t检验,P < 0.0001)。与接受蒿甲醚 - 本芴醇治疗的个体相比,接受青蒿琥酯 - 阿莫地喹治疗的个体属于高发病率组的几率更高(优势比[OR],2.24;95%置信区间,1.03 - 4.83,P = 0.041),而接受双氢青蒿素 - 哌喹治疗的个体属于高发病率组的几率较低(OR:0.30,95%置信区间,0.11 - 0.85;P = 0.024)。与居住在布古拉 - 哈莫1半城市地区的个体相比,居住在索库拉尼和卡拉莫戈布古森林地区的个体属于高发病率组的几率显著更高(卡拉莫戈布古:OR,3.68;95%置信区间,1.46 - 9.31;P = 0.0059;索库拉尼:OR,11.46;95%置信区间,4.49 - 29.2;P < 0.0001)。这项研究强调了即使在分区层面精细划分疟疾风险对于有针对性和定制化干预措施的重要性。